Source-grounded facts extracted from Immunome Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Immunome Inc. shareholders approved Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation at the 2026-06-09 meeting.
“The Company’s stockholders indicated, on an advisory basis, their preference for the frequency of stockholder advisory votes on the compensation of the Company’s named executive officers. The final voting results are as follows: 1 Year 2 Years 3 Years Abstentions Broker Non-Votes 91,949,591 368,407 41,534 22,034 11,768,578”
Immunome Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-09 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 90,908,436 1,442,116 31,014 11,768,578”
Immunome Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.
“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the Audit Committee of the Company’s Board of Directors. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 104,100,900 27,134 22,110 -”
Immunome Inc. shareholders approved Election of Directors at the 2026-06-09 meeting.
“The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes James Boylan 70,209,570 22,171,996 11,768,578 Sandra Swain, M.D. 92,157,301 224,265 11,768,578 Philip Wagenheim 92,162,632 218,934 11,768,578”
Immunome Inc. reported the quarter ended March 31, 2026 results: net income net loss of $53.8 million.
“Immunome reported a net loss of $53.8 million for the quarter ended March 31, 2026.”
Immunome Inc. completed an acquisition involving Zentalis Pharmaceuticals, Inc. for 1,805,502 shares of Company common stock (closed 2024-10-25).
“the customary rights and obligations of a sole owner (the “Asset Purchase”). Under the Purchase Agreement, in consideration of the Asset Purchase, the Company issued to Zentalis 1,805,502 shares of Company common stock (the “Shares”), described below under Stock Issuance Agreement . The Company is also obligated to pay Zentalis a one-time payment of $5,000,000 in”
Immunome Inc. reported first quarter ended March 31, 2024 results: net income net loss of $129.5 million, EPS basic and diluted net loss per share attributable to common stockholders of $2.51.
“Immunome, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2024”
Max Rosett was appointed as principal accounting officer at Immunome Inc..
“the Company’s board of directors appointed Max Rosett, in addition to his other titles, as the Company’s principal accounting officer effective immediately upon the effectiveness of Mr. Lapetina’s resignation.”
Bob Lapetina departed as Vice President, Finance, Corporate Controller, and principal accounting officer at Immunome Inc..
“Bob Lapetina notified Immunome, Inc. (the “Company”) that he will be resigning from his positions as the Company’s Vice President, Finance, Corporate Controller, and principal accounting officer to pursue other opportunities.”
Sandra Swain was appointed as Class III Director at Immunome Inc..
“appointed Sandra Swain, M.D. as a Class III director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders.”
Immunome Inc. reported the full-year ended December 31, 2023 results: net income $106.8 million, EPS $5.38.
“Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.”
Immunome Inc. completed an acquisition involving Ayala Pharmaceuticals, Inc. for $20.0 million in cash (closed 2024-03-25).
“by reference. Item 2.01 Completion of Acquisition or Disposition of Assets Pursuant to the terms of the Asset Purchase Agreement, Immunome (i) paid an upfront purchase price of $20.0 million in cash to Ayala, less certain adjustments, (ii) issued Ayala 2 ,175,489 shares of Immunome’s common stock (the “Shares”), (iii) assumed specified liabilities from Ayala, and”
Immunome Inc. entered into BMS License with Bristol-Myers Squibb Company valued at up to approximately $142 million.
“In November 2017, Ayala entered into a License Agreement with Bristol-Myers Squibb Company (“BMS”), as amended by that certain First Amendment to License Agreement dated as of May 4, 2020 (the “BMS License”).”
Immunome Inc. entered into Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. valued at $20,000,000 (effective 2024-02-05).
“On February 5, 2024, Immunome, Inc. (the “Company”) and Ayala Pharmaceuticals, Inc. (“Ayala”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company will acquire Ayala’s AL101 and AL102 programs and assume certain of Ayala’s liabilities associated with the acquired assets”
Max Rosett changed role as Executive Vice President, Operations and Interim Chief Financial Officer at Immunome Inc..
“On January 31, 2024, the Board of Directors (the “Board”) of Immunome, Inc. (the “Company”) promoted Max Rosett, the Company’s Senior Vice President, Operations and Interim Chief Financial Officer to Executive Vice President, Operations and Interim Chief Financial Officer (the “Promotion”).”
Immunome Inc. entered into Stock Issuance Agreement with Zentalis Pharmaceuticals, Inc. (effective 2024-01-05).
“Concurrently with the execution of the License Agreement, the Company entered into a stock issuance agreement (the “Stock Issuance Agreement”) with Zentalis, pursuant to which the Company issued 2,298,586 shares of the Company’s common stock (the “Shares”), as partial consideration for the rights licensed to the Company from Zentalis pursuant to the License Agreement.”
Immunome Inc. entered into License Agreement with Zentalis Pharmaceuticals, Inc. valued at $35 million (effective 2024-01-05).
“On January 5, 2024, Immunome, Inc. (the “Company”) entered into a license agreement (“License Agreement”) with Zentalis Pharmaceuticals, Inc. (“Zentalis”), pursuant to which the Company received an exclusive, worldwide, royalty-bearing, sublicensable license under certain intellectual property relating to Zentalis’ proprietary antibody-drug conjugate (“ADC”) platform technology, ROR1 antibodies and ADCs targeting ROR1 to exploit products covered by or incorporating the licensed intellectual property rights.”
Carol Schafer was appointed as Class I Director at Immunome Inc..
“appointed Carol Schafer as a Class I director of the Company”
Bob Lapetina was appointed as Principal Accounting Officer at Immunome Inc..
“appointed Bob Lapetina, in addition to his other titles, as the Company’s principal accounting officer.”
Max Rosett was appointed as Interim Chief Financial Officer at Immunome Inc..
“appointed Max Rosett, in addition to his other titles, as the Company’s Interim Chief Financial Officer and principal financial officer.”
Corleen Roche departed as Chief Financial Officer at Immunome Inc..
“Ms. Roche will no longer serve as the Company’s Chief Financial Officer, principal financial officer or principal accounting officer.”
Immunome Inc. reported the third quarter ended September 30, 2023 results: revenue $4 million, net income Net loss ... was $4 million, or $(0.36) per share, EPS $(0.36) per share.
“in Q1 2025. Financial Highlights · Collaboration Revenue: Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended September 30, 2023 was $4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2023 were $4 million. · General and administrative (G&A) expenses: G&A expenses”
Jean-Jacques Bienaimé was appointed as Class II Director at Immunome Inc..
“appointed Jean-Jacques Bienaimé as a Class II director of the Company”
Immunome Inc.: Authorized Share Amendment to increase the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 (effective 2023-10-02).
“On October 2, 2023, in connection with the transactions contemplated by the Merger Agreement and following the Special Meeting, Immunome filed certificates of amendment to its Amended and Restated Certificate of Incorporation (the "Immunome Charter") (i) allowing for the exculpation of executive officers for certain breaches of fiduciary duty (the "Officer Exculpation Amendment") and (ii) increasing the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 (the "Authorized Share Amendment").”
Immunome Inc.: Officer Exculpation Amendment to Immunome's amended and restated certificate of incorporation allowing exculpation of executive officers for certain breaches of fiduciary duty (effective 2023-10-02).
“On October 2, 2023, in connection with the transactions contemplated by the Merger Agreement and following the Special Meeting, Immunome filed certificates of amendment to its Amended and Restated Certificate of Incorporation (the "Immunome Charter") (i) allowing for the exculpation of executive officers for certain breaches of fiduciary duty (the "Officer Exculpation Amendment") and (ii) increasing the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 (the "Authorized Share Amendment").”
Immunome Inc. shareholders approved To approve a postponement or adjournment of the Immunome special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal at the 2023-09-29 meeting.
“Proposal 5. To approve a postponement or adjournment of the Immunome special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Stock Issuance Proposal: 9,399,410 For 279,244 Against 9,364 Abstain 0 Broker Non-Votes”
Immunome Inc. shareholders approved To approve an amendment to the Immunome amended and restated certificate of incorporation to increase the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000 at the 2023-09-29 meeting.
“Proposal 4. To approve an amendment to the Immunome amended and restated certificate of incorporation to increase the number of authorized shares of Immunome common stock from 200,000,000 to 300,000,000: 9,405,265 For 267,373 Against 15,380 Abstain 0 Broker Non-Votes”
Immunome Inc. shareholders approved To approve an amendment to the Immunome amended and restated certificate of incorporation to provide for the exculpation of officers at the 2023-09-29 meeting.
“Proposal 3. To approve an amendment to the Immunome amended and restated certificate of incorporation to provide for the exculpation of officers: 7,472,296 For 108,915 Against 11,388 Abstain 2,095,419 Broker Non-Votes”
Immunome Inc. shareholders approved To approve an amendment to the Immunome 2020 Equity Incentive Plan to increase the total number of shares of Immunome common stock currently available for issuance under the 2020 Plan by 2,955,280 shares at the 2023-09-29 meeting.
“Proposal 2. To approve an amendment to the Immunome 2020 Equity Incentive Plan to increase the total number of shares of Immunome common stock currently available for issuance under the 2020 Plan by 2,955,280 shares: 6,051,180 For 1,534,559 Against 6,860 Abstain 2,095,419 Broker Non-Votes”
Immunome Inc. shareholders approved To approve the issuance of shares of Immunome capital stock pursuant to the Merger, which will represent more than 20% of the shares of Immunome common stock outstanding immediately prior to the Merger, pursuant to Rule 5635(a) of the Nasdaq Stock Market LLC (the 'Stock Issuance Proposal') at the 2023-09-29 meeting.
“Proposal 1. To approve the issuance of shares of Immunome capital stock pursuant to the Merger, which will represent more than 20% of the shares of Immunome common stock outstanding immediately prior to the Merger, pursuant to Rule 5635(a) of the Nasdaq Stock Market LLC (the “Stock Issuance Proposal”): 7,564,893 For 26,190 Against 1,516 Abstain 2,095,419 Broker Non-Votes”
Immunome Inc. underwent a change of control involving Morphimmune Inc. (closed 2023-10-02).
“On October 2, 2023, Immunome, Merger Sub and Morphimmune consummated the transactions contemplated by the Merger Agreement following a special meeting of Immunome’s stockholders on September 29, 2023 (the “Special Meeting”).”
Philip Wagenheim was appointed as Director at Immunome Inc..
“Philip Wagenheim 52 Class III Director”
James Boylan was appointed as Director at Immunome Inc..
“James Boylan 56 Class III Director”
Franklyn Prendergast, M.D., Ph.D. was appointed as Director at Immunome Inc..
“Franklyn Prendergast, M.D., Ph.D. 78 Class II Director”
Isaac Barchas was appointed as Director at Immunome Inc..
“Non-Employee Directors Isaac Barchas 56 Class II Director and Lead Independent Director”
Max Rosett was appointed as Senior Vice President, Operations at Immunome Inc..
“Max Rosett 33 Senior Vice President, Operations”
Bruce Turner, M.D., Ph.D. was appointed as Chief Strategy Officer at Immunome Inc..
“Bruce Turner, M.D., Ph.D. 60 Chief Strategy Officer”
Sandra Stoneman was appointed as Chief Legal Officer and General Counsel at Immunome Inc..
“Sandra Stoneman 51 Chief Legal Officer and General Counsel”
Corleen Roche was appointed as Chief Financial Officer at Immunome Inc..
“Corleen Roche 57 Chief Financial Officer”
Matthew Robinson, Ph.D. was appointed as Chief Discovery Officer, Biology at Immunome Inc..
“Matthew Robinson, Ph.D. 54 Chief Discovery Officer, Biology”
Jack Higgins, Ph.D. was appointed as Chief Scientific Officer at Immunome Inc..
“Jack Higgins, Ph.D. 44 Chief Scientific Officer”
Clay Siegall, Ph.D. was appointed as Chief Executive Officer, President, Chairman of the Board and Class I Director at Immunome Inc..
“Clay Siegall, Ph.D. 63 Chief Executive Officer, President, Chairman of the Board and Class I Director”
Dennis Giesing, Ph.D. was terminated as Chief Development Officer at Immunome Inc..
“Dennis Giesing, Ph.D., Immunome’s former Chief Development Officer, was terminated as an officer and employee of Immunome effective as of the closing of the Merger.”
Purnanand D. Sarma, Ph.D. resigned as Director and Officer at Immunome Inc..
“Purnanand D. Sarma, Ph.D. resigned from Immunome’s board of directors and any respective committee membership of Immunome’s board of directors, and resigned as an officer and employee of Immunome”
Michael Lefenfeld resigned as Director at Immunome Inc..
“each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors”
John LaMattina, Ph.D. resigned as Director at Immunome Inc..
“each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors”
Richard Baron resigned as Director at Immunome Inc..
“each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors”
Michael Rapoport resigned as Director at Immunome Inc..
“each of Michael Rapoport, Richard Baron, John LaMattina, Ph.D., and Michael Lefenfeld resigned from Immunome’s board of directors”
Immunome Inc. reported the second quarter ended June 30, 2023 results: net income $5.6 million, or $0.46 per share, EPS $0.46 per share.
“Net loss for the three months ended June 30, 2023 was $5.6 million, or $0.46 per share.”
Immunome Inc. entered into Agreement and Plan of Merger and Reorganization with Morphimmune Inc. (effective 2023-06-29).
“On June 29, 2023, Immunome, Inc., a Delaware corporation (“Immunome”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Morphimmune Inc., a Delaware corporation (“Morphimmune”), a biotechnology company focused on developing targeted oncology therapeutics, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Immunome (“Merger Sub”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.